Head to Head Review: Beam Therapeutics (NASDAQ:BEAM) vs. AVROBIO (NASDAQ:AVRO)

Beam Therapeutics (NASDAQ:BEAMGet Rating) and AVROBIO (NASDAQ:AVROGet Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Risk & Volatility

Beam Therapeutics has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Beam Therapeutics and AVROBIO, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics 0 2 6 0 2.75
AVROBIO 0 0 1 0 3.00

Beam Therapeutics currently has a consensus price target of $76.33, indicating a potential upside of 114.96%. AVROBIO has a consensus price target of $4.00, indicating a potential upside of 222.58%. Given AVROBIO’s stronger consensus rating and higher possible upside, analysts plainly believe AVROBIO is more favorable than Beam Therapeutics.


This table compares Beam Therapeutics and AVROBIO’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Beam Therapeutics -474.54% -37.58% -20.78%
AVROBIO N/A -82.47% -66.62%

Institutional & Insider Ownership

76.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 55.7% of AVROBIO shares are owned by institutional investors. 4.0% of Beam Therapeutics shares are owned by insiders. Comparatively, 6.4% of AVROBIO shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Beam Therapeutics and AVROBIO’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Beam Therapeutics $60.92 million 42.20 -$289.09 million ($4.13) -8.60
AVROBIO N/A N/A -$119.13 million ($2.49) -0.50

AVROBIO has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.


AVROBIO beats Beam Therapeutics on 7 of the 13 factors compared between the two stocks.

About Beam Therapeutics

(Get Rating)

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.


(Get Rating)

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm’s clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.

Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.